As The Going Gets Tough, Indian Generic Makers Turn To The Land Of The Rising Sun
This article was originally published in The Pink Sheet Daily
Executive Summary
Structural shifts in the Japanese pharmaceutical landscape, low generic penetration, a number of patent expiries in the next three years and an increasingly unattractive U.S. climate drive Indian firms to the Japanese market.